PFKP KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.
HeLa
Human
Cervix
Sanger Sequencing, Western blot
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.
1200015H23Rik, 6 phosphofructokinase, platelet type, 6-phosphofructokinase, 6-phosphofructokinase type C, 9330125N24Rik, FLJ40226, K6PP, K6PP_HUMAN, MGC105718, PFK, fibroblast type, PFK-C, PFKF, PFKP, Phosphofructo-1-kinase isozyme C, Phosphofructokinase 1, Phosphofructokinase platelet, Phosphohexokinase, platelet type
PFKP KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.
1200015H23Rik, 6 phosphofructokinase, platelet type, 6-phosphofructokinase, 6-phosphofructokinase type C, 9330125N24Rik, FLJ40226, K6PP, K6PP_HUMAN, MGC105718, PFK, fibroblast type, PFK-C, PFKF, PFKP, Phosphofructo-1-kinase isozyme C, Phosphofructokinase 1, Phosphofructokinase platelet, Phosphohexokinase, platelet type
HeLa
Human
Cervix
Sanger Sequencing, Western blot
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon3.
Adenocarcinoma
PFKP
Knockout
CRISPR technology
Sanger Sequencing, Western blot
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
EU: 2 US: 2
Adherent
Female
Ambient - Can Ship with Ice
-20°C
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
This supplementary information is collated from multiple sources and compiled automatically.
PFKP also known as 6-phosphofructokinase platelet type functions as an important glycolytic enzyme that catalyzes the phosphorylation of fructose 6-phosphate to fructose 16-bisphosphate using ATP. This process shows the rate-limiting step in glycolysis. The PFKP protein weighs approximately 85 kDa. Expression occurs in various tissues with high presence in platelets and muscle tissues indicating its significant role in energy metabolism.
PFKP plays an essential role in maintaining energy supply ensuring efficient glycolysis during high energy demands. It associates with other isoforms PFKM (muscle) and PFKL (liver) to form a tetrameric complex which can adapt its activity based on the energy needs of the cell. This adaptability defines its contribution to cellular metabolism regulation considering energy substrates and signaling molecules.
The function of PFKP ties closely to glycolysis and the larger metabolic pathways managing energy production such as the tricarboxylic acid (TCA) cycle. Within these pathways PFKP interacts with other metabolic regulators including AMP-activated protein kinase (AMPK) which influences cell metabolism in response to energy availability. Connections with PFKL and PFKM reveal that PFKP's activity relates to the overall glycolytic flux and energy balance.
PFKP's alterations contribute to metabolic conditions like cancer and diabetes. Its dysregulation in cancer cells supports the Warburg effect where tumor cells prefer glycolysis. The link with metabolic proteins such as AMPK also indicates a potential role in diabetes as both disorders involve shifts in energy metabolism. Understanding PFKP's impact on these diseases helps in developing therapeutic strategies targeting metabolic pathways.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lane 1: Wild-type HeLa cell lysate (20 ug)
Lane 2: PFKP knockout HeLa cell lysate (20 ug)
Lane 3: Jurkat cell lysate (20 ug)
Lanes 1-3: Merged signal (red and green). Green - Anti-PFKP antibody [OTI1D6] ab119796 observed at 86 kDa. Red - loading control Anti-GAPDH antibody [EPR16891] - Loading Control ab181602 observed at 36 kDa.
Anti-PFKP antibody [OTI1D6] ab119796 Anti-PFKP antibody [OTI1D6] was shown to specifically react with PFKP in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human PFKP knockout HeLa cell line ab265136 (knockout cell lysate ab257580) was used. Wild-type and PFKP knockout samples were subjected to SDS-PAGE. Anti-PFKP antibody [OTI1D6] ab119796 and Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) and Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-PFKP antibody [OTI1D6] (Anti-PFKP antibody [OTI1D6] ab119796) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: PFKP knockout HeLa cell lysate at 20 µg
Lane 3: Jurkat cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) at 1/10000 dilution
Predicted band size: 86 kDa
Observed band size: 86 kDa
Lanes 1-3: Merged signal (red and green). Green - Anti-PFKP antibody [OTI1D6] ab119796 observed at 86 kDa. Red - loading control Anti-GAPDH antibody [EPR16891] - Loading Control ab181602 observed at 36 kDa.
Anti-PFKP antibody [OTI1D6] ab119796 Anti-PFKP antibody [OTI1D6] was shown to specifically react with PFKP in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human PFKP knockout HeLa cell line ab265136 (knockout cell lysate ab257580) was used. Wild-type and PFKP knockout samples were subjected to SDS-PAGE. Anti-PFKP antibody [OTI1D6] ab119796 and Anti-GAPDH antibody[EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) and Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
Homozygous: 1 bp insertion in exon3
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com